PMCB Material Contracts | PHARMACYTE BIOTECH, INC.

PHARMACYTE BIOTECH, INC. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-04-02: Form 8-K; Exhibit 10.1; Description 2022 INCENTIVE STOCK PLAN, AS AMENDED.
2025-10-31: Form 8-K; Exhibit 10.1; Description PHARMACYTE BIOTECH, INC. 2022 EQUITY INCENTIVE PLAN, AS AMENDED.
2025-09-05: Form 8-K; Exhibit 10.4; Description REGISTRATION RIGHTS AGREEMENT, DATED SEPTEMBER 2, 2025.
2025-09-05: Form 8-K; Exhibit 10.3; Description FORM OF WARRANT OF TNF PHARMACEUTICALS, INC.

Filed	Form	Exhibit	Description
2026-04-02	8-K	10.1	2022 INCENTIVE STOCK PLAN, AS AMENDED
2025-10-31	8-K	10.1	PHARMACYTE BIOTECH, INC. 2022 EQUITY INCENTIVE PLAN, AS AMENDED
2025-09-05	8-K	10.4	REGISTRATION RIGHTS AGREEMENT, DATED SEPTEMBER 2, 2025
2025-09-05	8-K	10.3	FORM OF WARRANT OF TNF PHARMACEUTICALS, INC
2025-09-05	8-K	10.2	FORM OF CERTIFICATE OF DESIGNATIONS OF SERIES H CONVERTIBLE PREFERRED STOCK OF TNF PHARMACEUTICALS, INC.
2025-09-05	8-K	10.1	SECURITIES PURCHASE AGREEMENT, DATED SEPTEMBER 2, 2025
2025-08-18	8-K	10.3	ENGAGEMENT LETTER, DATED AUGUST 17, 2025 BY AND BETWEEN PHARMACYTE BIOTECH, INC. AND GP NURMENKARI INC.
2025-08-18	8-K	10.2	FORM OF REGISTRATION RIGHTS AGREEMENT
2025-08-18	8-K	10.1	FORM OF PURCHASE AGREEMENT
2025-08-11	10-K	10.43	EXECUTIVE COMPENSATION AGREEMENT
2024-05-23	8-K	10.5	REGISTRATION RIGHTS AGREEMENT, DATED MAY 20, BY AND AMONG PHARMACYTE BIOTECH, INC. AND MYMD PHARMACEUTICALS, INC.
2024-05-23	8-K	10.4	FORM OF SHORT-TERM WARRANT OF MYMD PHARMACEUTICALS, INC.
2024-05-23	8-K	10.3	FORM OF LONG-TERM WARRANT OF MYMD PHARMACEUTICALS, INC.
2024-05-23	8-K	10.2	FORM OF CERTIFICATE OF DESIGNATIONS OF SERIES G CONVERTIBLE PREFERRED STOCK OF MYMD PHARMACEUTICALS, INC.
2024-05-23	8-K	10.1	SECURITIES PURCHASE AGREEMENT, DATED MAY 20, BY AND AMONG PHARMACYTE BIOTECH, INC. AND MYMD PHARMACEUTICALS, INC.
2023-11-16	8-K	10.4	FORM OF COLLABORATION AGREEMENT
2023-11-16	8-K	10.3	FORM OF REGISTRATION RIGHTS AGREEMENT
2023-11-16	8-K	10.2	FORM OF CONVERTIBLE NOTE
2023-11-16	8-K	10.1	FORM OF PURCHASE AGREEMENT
2023-05-11	8-K	10.3	AGREEMENT
2023-05-11	8-K	10.2	REGISTRATION RIGHTS AGREEMENT
2023-05-11	8-K	10.1	SECURITIES PURCHASE AGREEMENT
2022-10-14	8-K	10.1	RELEASE AGREEMENT
2022-10-07	8-K	10.1	SEPARATION, CONSULTING AND RELEASE AGREEMENT
2022-08-16	8-K	10.2	DIRECTOR OFFER LETTER
2022-08-16	8-K	10.1	COOPERATION AGREEMENT
2022-07-28	10-K	10.42	PHARMACYTE BIOTECH, INC. 2021 EQUITY INCENTIVE PLAN.
2022-07-28	10-K	10.41	AMENDED AND RESTATED EXECUTIVE COMPENSATION AGREEMENT, DATED MAY 8, 2022, BETWEEN CARLOS A. TRUJILLO AND THE COMPANY.
2022-07-28	10-K	10.40	AMENDED AND RESTATED EXECUTIVE COMPENSATION AGREEMENT, DATED MAY 8, 2022, BETWEEN KENNETH L. WAGGONER AND THE COMPANY.
2021-08-23	8-K	10.1	SECURITIES PURCHASE AGREEMENT, DATED AS OF AUGUST 19, 2021
2020-10-16	8-K	10.1	AMENDMENT NO. 3 TO EXECUTIVE COMPENSATION AGREEMENT
2020-09-11	10-Q	10.2	AMENDMENT NO. 1 TO RIGHT OF FIRST REFUSAL AGREEMENT
2020-09-11	10-Q	10.1	RIGHT OF FIRST REFUSAL AGREEMENT
2020-01-21	8-K	10.1	SHARE SUBSCRIPTION AGREEMENT
2018-05-15	8-K	10.3	SECOND AMENDMENT TO LICENSING AGREEMENT
2018-05-15	8-K	10.2	THIRD AMENDMENT TO LICENSING AGREEMENT
2018-05-15	8-K	10.1	FOURTH ADDENDUM TO ASSET PURCHASE AGREEMENT
2018-02-22	8-K	10.2	MUTUAL TERMINATION AGREEMENT
2018-02-22	8-K	10.1	ENGAGEMENT LETTER WITH AEON CAPITAL
2017-10-10	8-K	10.1	DIRECTOR LETTER AGREEMENT
2017-09-06	8-K	10.1	BINDING TERM SHEET
2017-07-10	8-K	10.1	DIRECTOR OFFER LETTER
2017-05-02	8-K	10.1	LETTER AGREEMENT
2017-03-13	10-Q	10.7	AMENDMENT #1 TO DIRECTOR OFFER LETTER
2017-03-13	10-Q	10.6	FOURTH STOCK OPTION AGREEMENT - KENNETH L. WAGGONER
2017-03-13	10-Q	10.5	THIRD STOCK OPTION AGREEMENT - CARLOS A. TRUJILLO
2017-03-13	10-Q	10.4	FOURTH STOCK OPTION AGREEMENT - GERALD W. CRABTREE
2017-03-13	10-Q	10.3	EXECUTIVE COMPENSATION AGREEMENT - GERALD W. CRABTREE
2017-03-13	10-Q	10.2	EXECUTIVE COMPENSATION AGREEMENT - CARLOS A. TRUJILLO
2017-03-13	10-Q	10.1	EXECUTIVE COMPENSATION AGREEMENT - KENNETH L. WAGGONER
2016-12-21	8-K	10.1	AMENDMENT TO ENGAGEMENT LETTER
2016-12-02	10-Q	10.1	SECOND AMENDMENT TO LICENSE AGREEMENT
2016-07-29	10-K	10.38	Binding Memorandum of Understanding dated as of July 28, 2016, between the Company and Austrianova Singapore Pte Ltd.
2016-07-29	10-K	10.37	FIRST AMENDMENT TO LICENSING AGREEMENT
2016-07-29	10-K	10.36	VARIATION TO LICENSE AGREEMENT
2016-07-29	10-K	10.31	SECOND AMENDMENT TO LICENSING AGREEMENT
2016-07-29	10-K	10.30	FIRST AMENDMENT TO LICENSING AGREEMENT
2016-03-08	10-Q	10.4	STOCK OPTION AGREEMENT
2016-03-08	10-Q	10.3	STOCK OPTION AGREEMENT
2016-03-08	10-Q	10.2	AMENDMENT TO EXECUTIVE COMPENSATION AGREEMENT
2016-03-08	10-Q	10.1	AMENDMENT TO EXECUTIVE COMPENSATION AGREEMENT
2016-01-12	8-K	10.2	STOCK AND WARRANT PURCHASE AGREEMENT
2016-01-12	8-K	10.1	STOCK AND WARRANT PURCHASE AGREEMENT
2015-04-29	8-K	10.1	AGREEMENT LETTER
2015-03-13	10-Q	10.7	SECOND STOCK OPTION AGREEMENT
2015-03-13	10-Q	10.6	FIRST STOCK OPTION AGREEMENT
2015-03-13	10-Q	10.5	EXECUTIVE COMPENSATION AGREEMENT
2015-03-13	10-Q	10.4	SECOND STOCK OPTION AGREEMENT
2015-03-13	10-Q	10.3	FIRST STOCK OPTION AGREEMENT
2015-03-13	10-Q	10.2	EXECUTIVE COMPENSATION AGREEMENT BETWEEN THE COMPANY AND KENNETH L. WAGGONER DATED MARCH 10, 2015
2014-12-15	10-Q	10.22	LICENSING AGREEMENT
2014-10-17	10-K/A	10.13	MASTER AGREEMENT
2014-10-17	10-K/A	10.12	LICENSE AGREEMENT
2014-10-17	10-K/A	10.11	RESEARCH AGREEMENT
2014-10-03	8-K	10.6	STOCK OPTION AGREEMENT
2014-10-03	8-K	10.5	CONSULTING AGREEMENT
2014-10-03	8-K	10.4	STOCK OPTION AGREEMENT
2014-10-03	8-K	10.3	CONSULTING AGREMENT
2014-10-03	8-K	10.2	STOCK OPTION AGREEMENT
2014-10-03	8-K	10.1	CONSULTING AGREEMENT
2014-09-25	8-K	10.2	ASSET PURCHASE AGREEMENT
2014-09-25	8-K	10.1	SETTLEMENT AGREEMENT
2014-08-04	10-K	10.10	EMPLOYMENT AGREEMENT
2014-08-04	10-K	10.9	MEMORANDUM OF UNDERSTANDING
2014-08-04	10-K	10.7	MASTER CONSULTANCY AGREEMENT
2014-08-04	10-K	10.6	CONSULTING AGREEMENT
2014-08-04	10-K	10.4	MANUFACTURING FRAMEWORK AGREEMENT
2014-08-04	10-K	10.4	MASTER SERVICES AGREEMENT
2014-08-04	10-K	10.2	AMENDMENT TO LICENSE AGREEMENNT
2014-08-04	10-K	10.1	LICENSE AGREEMENT
2014-05-29	8-K	10.1	FINANCIAL ADVISORY, OFFERING AND AT THE MARKET OFFERING ENGAGEMENT LETTER
2014-03-25	8-K	10.1	LETTER AGREEMENT
2014-02-19	8-K	10.1	PURCHASE AGREEMENT
2010-03-22	10-Q	10.1	REAL ESTATE SALE AGREEMENT
2009-08-13	10-K	10	exhibit103.htm

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
AIM ImmunoTech Inc. (AIM)	United States	$0.006B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)	United States	$0.006B
WINDTREE THERAPEUTICS INC /DE/ (WINT)	United States	$0.003B	-0.32
VivoSim Labs, INC. (VIVS)	United States	$0.003B
Calidi Biotherapeutics, Inc. (CLDI)	United States	$0.003B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)	United States	$0.007B
CURIS INC (CRIS)	United States	$0.002B	-0.05
Silexion Therapeutics Corp (SLXN)		$0.001B
TScan Therapeutics, Inc. (TCRX)	United States	$0.008B	-1.23
Senti Biosciences Holdings, Inc. (SNTI)	United States	$0.011B	-0.70